Janan malik biography of albert einstein
•
First experiments with ultrashort, circularly polarized soft X-ray pulses at FLASH2
S. Marotzke Deutsches Elektronen-Synchrotron, DESY, Notkestraße 85, 22607 Hamburg, Germany Institut für Experimentelle und Angewandte Physik, Christian-Albrechts-Universität zu Kiel, Olshausenstr. 40, 24098 , 24118 Kiel, Germany D. Gupta Helmholtz-Zentrum Berlin für Materialien und Energie, Albert-Einstein-Str. 15, 12489 Berlin, Germany R.-P. Wang Deutsches Elektronen-Synchrotron, DESY, Notkestraße 85, 22607 Hamburg, Germany M. Pavelka Department of Physics and Astronomy, Uppsala University, Box 256, 751 05 Uppsala, Sweden S. Dziarzhytski Deutsches Elektronen-Synchrotron, DESY, Notkestraße 85, 22607 Hamburg, Germany C. von Korff Schmising Max Born Institute for Nonlinear Optics and Short Pulse Spectroscopy, Max-Born Straße 2A, 12489 Berlin, Germany S. Jana Max Born Institute for Nonlinear Optics and Short Pulse Spectroscopy, Max-Born Straße 2A, 12489 Berlin, Germany N. Thielemann-Kühn Freie Universi
•
Editors
Scientific Reports is run by a team of experienced editors who are experts in their fields. From our Editorial Board Members and Senior Editorial Board to our in-house Editors, we work togetherResearch integrity issue to ensure that your research is expertly handled and that we consider it to be technically sound, scientifically valid, and ultimately suitable for publication.
Interview with Rafal Marszalek, Chief Editor of Scientific Reports
In-house Editors
Chief Editor: Rafal Marszalek, PhD; Springer Nature, UK
Rafal's background is analytical and biological chemistry. He did his PhD and postdoctoral research in single-cell proteomics at Imperial College London, UK. He was an editor at Genome Biology before joining Scientific Reports in August 2016.
ORCID 0000-0003-0316-1363
Deputy Editor: Elizabeth Mann, PhD; Springer natur, UK
Elizabeth has a background in pharmacology and completed her PhD in neuropharmacology at King's Col
•
Abstract
Common chronic diseases represent the greatest driver of rising healthcare costs, as well as declining function, independence, and quality of life. Geroscience‐guided approaches seek to delay the onset and progression of multiple chronic conditions by targeting fundamental biological pathways of aging. This approach is more likely to improve overall health and function in old age than treating individual diseases, by addressing aging the largest and mostly ignored risk factor for the leading causes of morbidity in older adults. Nevertheless, challenges in repurposing existing and moving newly discovered interventions from the bench to clinical care have impeded the progress of this potentially transformational paradigm shift. In this article, we propose the creation of a standardized process for evaluating FDA‐approved medications for their geroscience potential. Criteria for systematically evaluating the existing literature that spans from animal models to human studies w